Benzinga | Feb 4, 2021 01:17PM EST

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $198

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $145 to $198.